MIG, Recombinant, Mouse (Monokine induced by Interferon Gamma)

CXCL9 is a chemoattractant for activated T cells and possess angiostatic activity. Both CXCL9 and CXCL10 have been considered as important components for the anti-tumor activities of interferon-gamma (IFNgamma) and interleukin-12 in animal models. Mouse MIG is induced in THP-1 cells and in peripheral blood mononuclear cells by interferon-gamma but not by interferon-alpha or by lipopolysaccharide. Analysis of mouse and human genomic DNAs suggested that the Mumig and Humig genes are true mouse-human homologues.\n\nDescription: \nRecombinant Mouse MIG (monokine induced by gamma-interferon ) produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 105 amino acids and having a molecular mass of 12208 Dalton. Recombinant Mouse MIG is purified by proprietary chromatographic techniques.\n\nAmino Acid Sequence: \nThe sequence of the first five N-terminal amino acids was determined and was found to be, Thr-Leu-Val-Ile-Arg.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nMIG is fully biologically active when compared to standard. The Activity is calculated by the ability to chemoattract Human lymphocytes using a concentration of 0.1-1 ng/ml.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of Murine MIG.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm .\n2. Analysis by RP-HPLC, using a calibrated solution of Murine MIG as a Reference Standard.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized MIG in sterile 18MOmega-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized MIG although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution MIG should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M3949-05A

Size

5ug

Form

Supplied as a lyophilized powder without additives.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Evaluation of cytokines (MIG, IFN-gamma, TNF-alpha, IL-4, IL-5, and IL-10) during the different evolutive phases of chagasic esophagopathy.\n\nClin Immunol 2006 May;119(2):213-8\n\n2. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts.\n\nClin Exp Immunol 2005 Aug;141(2):363-71\n\n3. Accumulation of CXCR3-expressing eosinophils and increased concentration of its ligands (IP10 and Mig) in bronchoalveolar lavage fluid of patients with chronic eosinophilic pneumonia.\n\nInt Arch Allergy Immunol 2005 Jul;137(3):229-35\n\n4. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG).\n\nJ Am Soc Nephrol 2005 Jun;16(6):1849-58\n\n5. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.\n\nOncogene 2005 Jun 30;24(28):4540-8\n\n6. Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes.\n\nInvest Ophthalmol Vis Sci 2005 May;46(5):1668-74